You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
Optical photothermal IR (O-PTIR) microscopy for chemical imaging of living cells at sub-micron resolutionSBC: PHOTOTHERMAL SPECTROSCOPY CORP. Topic: 102
Optical photothermal IR (OPTIR) microscopy for chemical imaging of living cells at sub-micron resolution Project Summary/Abstract Photothermal Spectroscopy Corp (PSC) and Prof. Ji-Xin Cheng of Boston University in collaboration with Prof. Rohith Reddy (University of Houston) propose to develop, validate, and commercialize a novel technical called Optical Photothermal Infrared (OPTIR) spectroscopy. ...STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
Nanoparticle-based Intraperitoneal Delivery of Combined Chemo-brachytherapy for Treatment of Ovarian Cancer MetastasesSBC: Nami Therapeutics Corp. Topic: 102
PROJECT SUMMARY ABSTRACT Ovarian cancer is the second most common gynecologic cancer in the United States and the most common cause of death among women with gynecologic malignanciesDespite advances in treatment strategiesperitoneal metastasis remains the primary cause of morbidity and mortality in ovarian cancerThe National Cancer Research Institute Clinical and Translational Radiotherapy Researc ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: Elimu Informatics, Inc. Topic: 172
PROJECT SUMMARY Treatment with convalescent plasma (CP) was recently approved by the FDA for seriously ill patients of COVID-19. There are many institutions and hospitals that have implemented CP programs, but they all face the challenge of finding sufficient and appropriate donors. The constraints of matching, imbalances in supply and demand, and privacy concerns pose several challenges to engage ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: Biospyder Technologies, Inc. Topic: 172
SummaryThis Phase I program will develop TempO Splicea highly multiplexed targeted sequencing assay monitoring RNA Binding ProteinRBPsplicing expression and alternatively splicedASmRNA representatives of coregulated splicing modulesa novel variation of the TempO Seqassay used for high throughput screeningdesigned to address the hypothesis that it is possible to provide a surrogate assay of the who ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: Cetya Therapeutics, Inc. Topic: NHLBI
PROJECT SUMMARY The β-hemoglobinopathies are prevalent genetic blood diseases with few treatment options. It is estimate that 7% of the worldandapos;s population carries an abnormal hemoglobin gene with 400,000 infants born annually with a severe life threatening hemoglobinopathy. Drug mediated induction of normal, but developmentally silenced, fetal hemoglobin (HbF) expression reduces anemia and ...STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: Technology Commercialization Partners LLC Topic: OD
PROJECT SUMMARYABSTRACT To datethe standard method to access a mouse tail vein is manual injectionbut its yield rate is poor in generalThis leads to multiple needle insertions associated with tissue damage and painBesidesfailure in tail vein injection leads to data lossand thereby more animals will be required to compensate itFinallythe dose variation induced by unreliable injection increases erro ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: BIOVINC, LLC Topic: 102
ABSTRACTBreast CancerBCis the leading cause of cancer death for woman in the USBreast cancer is treated by a combination of surgeryradiationand various types of chemo and targeted therapeutic strategiesApproximately half of patients who have positive sentinel lymph nodes at surgeryand as many asof patients who do noteventually present with metastatic diseaseOverof BC patients eventually have skele ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: Lacerta Therapeutics, Inc. Topic: 102
Glioblastoma (GBM) is the most lethal form of adult brain cancers with a median survival of andlt;15 months despite aggressive standard chemoradiation. GBM are formed by GBM stem-like cells (GSCs) - a major contributor to tumor recurrence and a natural focus for therapeutic development. There are two main reasons responsible for treatment failure: 1) high intra- and inter-tumor cellular and molecu ...STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: TRICORDER ARRAY TECHNOLOGIES LLC Topic: 100
PROJECT SUMMARY The for profit small business concernTricorder Array Technologies LLCwill developin partnership with the University of Alabama at BirminghamSIDECAReSensing and Integrating Data for Environmental Conditions in Animal ResearchThis device will automate collection of relevant data that will enhance consistency in animal models used to study human health treatment researchOur innovative ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: PNEUMAX, LLC Topic: 113
PROJECT SUMMARYThree of top five causes of death in humans globally are lung relatedchronic obstructive pulmonary diseaseCOPDlower respiratory infections and lung cancers collectively account for over eight million deaths annuallyCurrentlyin preclinical settingstatic cell cultures and animal models are the most widely used systems for mechanistic and translational studiesHowevercritical limitation ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health